John McDonough's most recent trade in T2 Biosystems Inc was a trade of 18,182 Common Stock done at an average price of $1.2 . Disclosure was reported to the exchange on July 1, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| T2 Biosystems Inc | John McDonough | Director | Sale of securities on an exchange or to another person at price $ 1.16 per share. | 01 Jul 2021 | 18,182 | 516,386 (1%) | 0% | 1.2 | 21,091 | Common Stock |
| T2 Biosystems Inc | John McDonough | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 81,967 | 81,967 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John McDonough | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 45,454 | 534,568 (1%) | 0% | - | Common Stock | |
| T2 Biosystems Inc | John McDonough | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 45,454 | 45,454 | - | - | Restricted Stock Units | |
| T2 Biosystems Inc | John McDonough | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 45,454 | 45,454 | - | - | Restricted Stock Units |